SCHEDULE 13G: BlackRock Discloses 5.5% Passive Stake in Cidara Therapeutics

BlackRock, Inc. has filed a Schedule 13G, reporting a passive beneficial ownership of 5.5% of Cidara Therapeutics, Inc.'s common stock.

Summary

• BlackRock, Inc. has filed a Schedule 13G indicating beneficial ownership of 1,107,668 shares of Cidara Therapeutics, Inc. Common Stock.
• This ownership represents 5.5% of the total outstanding common shares of Cidara Therapeutics, Inc.
• BlackRock, Inc. holds sole voting power over 1,081,502 shares and sole dispositive power over 1,107,668 shares.
• The filing was made by BlackRock, Inc. as a parent holding company or control person.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The document is a standard passive ownership disclosure (Schedule 13G) and does not contain information that would inherently indicate positive or negative sentiment regarding the issuer's performance or outlook. It simply reports a beneficial ownership stake.

Future Outlook

NA

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

NA

Key Dates

Keywords

BlackRock, Cidara Therapeutics, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment